周三，美银证券调整了对诺和诺德公司（NYSE:NVO）股票的展望，将目标价从之前的166.00美元下调至159.50美元，同时维持对该股票的买入评级。这一调整是因为分析师预计第三季度集团销售额将达到约694亿丹麦克朗，同比增长18%，息税前利润（EBIT）将达到约330亿丹麦克朗，较上年同期增长23%。尽管有这些增长，预测的EBIT比共识预期低约4%。

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

It took GLP-1 medications like Ozempic just seven years to surpass insulin as the the second most common treatment for type 2 ...

Lottie Moss recently revealed she suffered a seizure from using Ozempic while Christina Aguilera was recently accused of ...

While the food industry has never met a diet trend it didn’t seek to capitalize on, GLP-1s at one point seemed to present an ...

Christina Aguilera sparked heated debates over her dramatic weight loss. On September 26, the 43-year-old singer visited ...

WeightWatchers' CEO of roughly two years, Sima Sistani, is out. She helped push the company into the white-hot weight-loss ...

Zmyra has become a standout natural alternative to Ozempic for weight loss. Reviewers for this article believe it to be the ...

Four months in, and what started as a sprint to skinny has turned into a leisurely crawl, with weight loss slowing to a ...

Zmyra stands out as a potent natural over-the-counter alternative to Ozempic. It provides a comprehensive weight loss ...

智通财经APP获悉，2024年，全球药品销售额排名预计将发生变动，艾伯维公司(ABBV.US)的Humira和辉瑞 (PFE.US )/BioNTech ( BNTX.US )的Comirnaty预计无法保持在前十名之内。取而代之的可能是诺和诺德 ( ...

Weight-loss drugs like Ozempic and Wegovy have become household names in recent years. But here's why they may not work for ...